Steatohepatitis/Metabolic Liver Disease News

Midlife women with a metabolic dysfunction-associated steatotic liver disease diagnosis were more likely to report severe or very severe hot flashes, though researchers found no direct link between the two conditions, data show.

Endoscopic sleeve gastroplasty with lifestyle intervention was more effective than lifestyle changes alone in achieving weight loss and histological improvement in patients with metabolic dysfunction-associated steatohepatitis and obesity.

Hispanic patients hospitalized for alcohol use disorder were more likely to develop alcohol-associated hepatitis, decompensated cirrhosis and related complications compared with non-Hispanic white patients, according to published data.

SAN DIEGO — Both FibroScan-aspartate aminotransferase and Agile 3+ scores “performed well” in predicting risk for advanced fibrosis in patients with metabolic dysfunction-associated steatohepatitis who had been treated with pegozafermin.

SAN DIEGO — Once-daily ALG-055009 achieved “significant and robust reductions” in liver fat at 12 weeks and was well-tolerated among noncirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to data.

SAN DIEGO — VK2809 demonstrated “robust reductions” in liver fat as early as 12 weeks in metabolic dysfunction-associated steatohepatitis, as well as MASH resolution and improvement in fibrosis by week 52, according to late-breaking data.

SAN DIEGO — Treatment with glucagon-like peptide-1 receptor agonists significantly reduced alanine aminotransferase among children with metabolic dysfunction-associated steatotic liver disease, especially those with type 2 diabetes.

SAN DIEGO — Semaglutide was superior to placebo in metabolic dysfunction-associated steatohepatitis resolution and improvement in fibrosis at 72 weeks, with a safety profile consistent with previous studies, according to late-breaking data.

SAN DIEGO — Patients with diabetes who were prescribed glucagon-like peptide-1 receptor agonists had lower odds of metabolic dysfunction-associated steatotic liver disease after liver transplantation, noted a presenter at The Liver Meeting.